Prolocor Unveils Results of Multicenter Study on Cardiovascular Risk in JACC

Prolocor Inc., a healthcare startup, announced the publication of its 800-patient study results in the Journal of the American College of Cardiology. This study utilized the Prolocor pFCG® test, which measures the expression of FcγRIIa on platelets to predict cardiovascular risks such as heart attack and stroke. The findings revealed that patients with high pFCG levels have over twice the risk of such events compared to those with low levels, emphasized by a hazard ratio of 2.09 (p=0.001).

This study addresses the substantial need for balancing antithrombotic therapy risks in acute coronary syndrome patients. Prolocor envisions its test as a vital tool for individualized antiplatelet therapy, aiding clinicians in decision-making to improve patient outcomes. The test has been evaluated in roughly 1,000 patients, consistently supporting its efficacy.